{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T19:35:39Z","timestamp":1769456139321,"version":"3.49.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"DOI":"10.1093\/cid\/ciu1159","type":"journal-article","created":{"date-parts":[[2015,1,13]],"date-time":"2015-01-13T03:22:38Z","timestamp":1421119358000},"page":"1102-1110","source":"Crossref","is-referenced-by-count":43,"title":["The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy"],"prefix":"10.1093","volume":"60","author":[{"given":"Eric L.","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton C.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Sax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. David","family":"Paltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rochelle P.","family":"Walensky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Freedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Losina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,1,12]]},"reference":[{"key":"key\n\t\t\t\t20170623072815_CIU1159C1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/505147","article-title":"The survival benefits of AIDS treatment in the United States","volume":"194","author":"Walensky","year":"2006","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAD.0b013e3283324283","article-title":"The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals","volume":"24","author":"Ray","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":"Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4(+) cell count is 0.200 to 0.350 X 10(9) cells\/L","volume":"139","author":"Wood","year":"2003","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/QAI.0b013e31819675e9","article-title":"The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time","volume":"50","author":"Lima","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/jir370","article-title":"The critical need for alternative antiretroviral formulations, and obstacles to their development","volume":"204","author":"Swindells","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C6","article-title":"Albuvirtide, the first long-acting HIV fusion inhibitor, suppressed viral replication in HIV-infected adults [abstract H-554]","author":"Wu","year":"2012"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C7","article-title":"TMC278 long acting\u2014a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers [abstract TUPE0042]","author":"Verloes","year":"2008"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1310\/hct1405-192","article-title":"Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor","volume":"14","author":"Spreen","year":"2013","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","article-title":"Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages","volume":"150","author":"Nowacek","year":"2011","journal-title":"J Control Release"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C11","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e328357f5ad","article-title":"Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice","volume":"26","author":"Dash","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C12","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/infdis\/jis395","article-title":"Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice","volume":"206","author":"Roy","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C13","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01529-09","article-title":"Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation","volume":"54","author":"Van't Klooster","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C15","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1128\/AAC.01235-13","article-title":"Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744","volume":"57","author":"Ford","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C16","article-title":"A study to investigate the safety, tolerability and pharmacokinetics of repeat dose administration of long-acting GSK1265744 and long-acting TMC278 intramuscular and subcutaneous injections in healthy adult subjects","author":"ViiV Healthcare, GlaxoSmithKline","year":"2013"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJM200103153441108","article-title":"The cost effectiveness of combination antiretroviral therapy for HIV disease","volume":"344","author":"Freedberg","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3851\/IMP2500","article-title":"Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease","volume":"18","author":"Schackman","year":"2013","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-158-2-201301150-00002","article-title":"Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States","volume":"158","author":"Walensky","year":"2013","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMsa054744","article-title":"The value of medical spending in the United States, 1960\u20132000","volume":"355","author":"Cutler","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C21","article-title":"Hidden costs, value lost: uninsurance in America","author":"Institute of Medicine","year":"2003"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"J Am Med Assoc"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C23","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/sim.3955","article-title":"Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected patients","volume":"29","author":"Noubary","year":"2010","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C24","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1086\/652650","article-title":"Late presentation for human immunodeficiency virus care in the United States and Canada","volume":"50","author":"Althoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.18553\/jmcp.2011.17.3.213","article-title":"Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV\/AIDS","volume":"17","author":"Hirsch","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C27","doi-asserted-by":"crossref","first-page":"e31591","DOI":"10.1371\/journal.pone.0031591","article-title":"Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States","volume":"7","author":"Sax","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/QAI.0b013e3182084b5a","article-title":"Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in C\u00f4te d'Ivoire","volume":"56","author":"Messou","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C29","author":"Red Book online","year":"2012"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/QAI.0b013e318258c696","article-title":"Establishment, retention, and loss to follow-up in outpatient HIV care","volume":"60","author":"Fleishman","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/QAD.0b013e32834fa15e","article-title":"Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study","volume":"26","author":"Helleberg","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C32","article-title":"HIV surveillance report: diagnosis of HIV infection in the United States and dependent areas, 2011","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C33","article-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2014"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C34","volume-title":"Medicaid drug price comparisons: average manufacturer price to published prices","author":"Department of Health and Human Services","year":"2005"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C35","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/QAD.0b013e328340a209","article-title":"A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV plus homeless and marginally housed people","volume":"24","author":"Bangsberg","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/cid\/cir537","article-title":"Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention","volume":"53","author":"Berg","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C38","article-title":"National HIV prevention progress report, 2013","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C39","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/QAD.0b013e328354bed6","article-title":"Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America","volume":"26","author":"Genberg","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1371\/journal.pone.0002783","article-title":"Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels","volume":"3","author":"Parienti","year":"2008","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/QAI.0000000000000025","article-title":"Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the Multisite Adherence Collaboration on HIV 14 study","volume":"64","author":"Wilson","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623072815_CIU1159C42","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/QAI.0b013e31825db0bd","article-title":"Racial\/ethnic disparities in ART adherence in the United States: findings from the MACH14 study","volume":"60","author":"Simoni","year":"2012","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/60\/7\/1102\/17853880\/ciu1159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T17:29:20Z","timestamp":1650994160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciu1159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,12]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,1,12]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciu1159","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1,12]]}}}